Academy of Medical Sciences of I.R. Iran Archives of Iranian Medicine 1029-2977 28 5 2025 05 01 Synergistic Effect of miR-383 and Cisplatin on Inhibition of Growth, Proliferation, and Migration of Lung Cancer Cells 264 274 10.34172/aim.33450 EN Vagef Elyaszadeh https://orcid.org/0009-0003-8817-7109 Maryam Tohidast https://orcid.org/0000-0003-4673-554X Seyed Samad Hosseini https://orcid.org/0000-0002-3722-4716 Mohammad Amini https://orcid.org/0000-0001-7543-9577 Parinaz Marami https://orcid.org/0009-0006-9115-1729 Behzad Baradaran https://orcid.org/0000-0002-8642-6795 Amir Ali Mokhtarzadeh https://orcid.org/0000-0002-4515-8675 Asiyeh Jebelli https://orcid.org/0000-0001-9494-2207 Journal Article 10.34172/aim.33450 2024 11 05 2025 02 26 Background: Lung cancer (LC) is a common life-threatening malignancy in humans. Cisplatin has been widely used in the treatment of various types of cancer. miR-383 is dysregulated in multiple cancers, and participates in tumorigenic processes, including apoptosis, proliferation, metastasis, and drug resistance. This study aimed to investigate the synergistic effect of miR-383 and cisplatin in LC. Methods: A549 cells were treated with cisplatin and miR-383 separately or in combination. Cell viability, apoptosis induction, stemness features, migratory capacity, and autophagy were measured by various methods. In addition, quantitative real-time PCR (qRT‐PCR) was used to evaluate the expression levels of genes involved in apoptosis, stemness, and migration. Results: The results demonstrated that miR-383 transfection in A549 cells increased their chemosensitivity to cisplatin, enhancing cisplatin-induced apoptosis (from 11.28% to 37.86%). This effect was mediated by regulating key genes such as Bcl-2 and Caspase-3 (P<0.0001). Moreover, the combination of miR-383 and cisplatin synergistically reduced cell migration and colony formation. It also downregulated metastatic and stemness-related genes, including MMP-2 and CD44, respectively (P<0.0001). Conclusion: The findings indicate that the combination treatment of miR-383 and cisplatin suppressed cell proliferation, migration and colony formation while enhancing the sensitivity of A549 cells to chemotherapy compared to monotherapy. These results suggest that miR-383 combination therapy warrants further investigation as a potential strategy for LC treatment.